Format

Send to

Choose Destination
Inflammopharmacology. 2006 Dec;14(5-6):256-9.

Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha.

Author information

1
University of Vermont, 2 Church Street, Burlington, VT 05401, USA. kast887@hotmail.com

Abstract

Aspirin and other cyclooxygenase inhibitors can increase levels of tumor necrosis factor-alpha and engage pro-apoptosis paths and/or anti-apoptosis paths. Seemingly conflicting data are briefly reviewed. Aspirin has been shown to slightly increase survival duration in multiple myeloma. In this brief note caution is raised about use of aspirin and COX inhibitors generally in inflammatory states and specifically in myeloma. Should they increase tumor necrosis factor-alpha they could exacerbate disease. A figure is presented showing the tendency for interleukin-6 and tumor necrosis factor-alpha, both demonstrated to be growth factors in myeloma, to be counter-regulated. Since both are now easily measured by specialty labs, it would be reasonable to monitor these during myeloma treatment generally, and particularly when using aspirin, COX inhibitors, or any other drug with potential to increase these growth factors.

PMID:
17139447
DOI:
10.1007/s10787-006-1532-6
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center